POSTER SETUP INFORMATION
TCLF Organizer:
Jonathan Wood & Associates
220 Kinderkamack Road, Suite C
Westwood, NJ 07675
Phone: 201-594-0400
Fax: 201-594-0409
Email: [email protected]
www.jwoodassoc.com
Onsite Contacts:
Damaris Cruz
Program Director
Email: [email protected]
Mobile: 201-983-7728
Venue:
Parc 55 Wyndham
55 Cyril Magnin Street
Market at Fifth
San Francisco, CA 94102
Hotel Contact:
Berit Rouse
Director of Catering & Convention Services
Email: [email protected]
Phone: (415) 403-6620
Ashlee Barton
Director of National Accounts
Email: [email protected]
Phone: 415-403-6627
Posters will be displayed in Cyril Magnin Foyer and will be available for viewing
1-hour pre/post the general session as well as during all food functions.
Posters will be displayed by section. Please refer to the “Poster Listing” for your
assigned poster number.
Poster Set-up:
Thursday, January 29
Open/Viewing Hours:
Thursday, January 29
Friday, January 30
Friday, January 30
9:00am – 1:00pm
Saturday, January 31
1:00pm – 10:00pm
7:00am – 8:30pm
6:00pm – 8:00pm (Poster Walk Reception-authors
must be present)
7:00am – 12:00pm
Dismantling:
Saturday, January 31
12:00pm – 1:00pm
Any posters and/or print materials left in the room after 1:00pm will be
discarded.
Poster dimensions:
- No larger than 4ft height x 4ft width
- There will be 2 posters displayed on each side of the same board.
Poster 1
4 ft
Poster 2
4 ft
4 ft
4 ft
4 ft
8 ft
SHIPPING INSTRUCTIONS:
Please send all shipments to the address below. For your convenience, we have
included sample shipping labels to clearly identify your package.
Attention: Berit Rouse, Catering Event
Parc 55 Wyndham San Francisco - Union Square
55 Cyril Magnin Street
San Francisco, CA 94102
Hold For: T-Cell Lymphoma Forum, January 29, 2015
To:
AUTHOR/POSTER PRESENTER NAME
c/o: Berit Rouse, Catering Services Mgr
Parc 55 Wyndham San Francisco - Union Square
55 Cyril Magnin Street
San Francisco, CA 94102
HOLD FOR: T-CELL LYMPHOMA FORUM
JANUARY 29, 2015
Poster #
Box #
of
SCHEDULE OF EVENTS
Venue
Parc 55 Wyndham San
Francisco - Union Square
55 Cyril Magnin Street
San Francisco, CA 94102
Phone: (415) 394-1111
Schedule of Events
Description
Timing
Location
Thursday, January 29
Exhibit & Poster set-up
9:00am – 1:00pm
Cyril Magnin Foyer
Exhibit & Poster Hall Open
1:00pm – 10:00pm
Cyril Magnin Foyer
General Session
2:00pm – 6:00pm
Cyril Magnin Ballroom
Welcome Dinner
6:00pm – 10:00pm
Embarcadero
Friday, January 30
Exhibit & Poster Hall Open
7:00am – 8:00pm
Cyril Magnin Foyer
Breakfast
7:00am – 8:30am
Cyril Magnin Foyer
General Session
8:30am – 6:30pm
Cyril Magnin Ballroom
Lunch Symposium
11:30am – 1:30pm
Embarcadero
Poster Walk Reception
6:00pm – 8:00pm
Cyril Magnin Foyer
Saturday, January 31
Exhibit/Poster Hall Open
7:00am – 1:00pm
Cyril Magnin Foyer
Breakfast
7:00am – 8:00am
Cyril Magnin Foyer
General Session
8:00am – 12:00pm
Cyril Magnin Ballroom
Boxed Lunch
12:00pm
Cyril Magnin Foyer
POSTER LISTING
Poster
number
First author’s
last name
Title
Molecular Pathogenesis (MP15)
MP15_1
Bachy, E
CD1d-restricted peripheral T-cell lymphoma
MP15_2
Merkel, O
Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation
MP15_3
Querfeld, C
MP15_4
Satou, A
Defining characteristics of T-memory cells and dendritic cells in the CTCL microenvironment
FoxP3-positive T-cell lymphoma arising in non-HTLV1 carrier: Clinicopathological analysis of 11 cases
of PTCL-NOS and 2 cases of mycosis fungoides
Global epidemiology of T-cell lymphoma (GE15)
GE15_1
Addasi, A
T cell lymphomas in JORDAN
GE15_2
Nishi, Y
Clinical features of aggressive adult T-cell leukemia/lymphoma in Okinawa prefecture
GE15_3
Perini, G
Anaplastic large cell lymphoma (ALCL): A Brazilian single center experience
Biological Therapies of T-cell lymphoma (BT15)
BT15_1
Bonnafous, C
BT15_2
Katsuya, H
BT15_3
Kim, Y
BT15_4
Nakagawa, M
BT15_5
Tobinai, K
BT15_6
Zinzani, PL
Excellent non clinical safety profile of IPH4102, the first anti-KIR3DL2 mAb for the treatment of CTCL
Colitis mimicking graft versus host disease during the treatment by a CCR4 monoclonal antibody,
mogamulizumab
Final results of phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides or
Sézary syndrome with detailed biomarker analysis
A Gain-of-function CCR4 mutations in adult T-cell leukemia/lymphoma (ATL) enhance the
chemotactic abilities and P13K/AKT activation
Ancillary analyses of a phase II study of mogamulizumab (KW-0761) in patients with CCR4-positive,
relapsed peripheral or cutaneous T-cell lymphomas
European phase 2 study of anti-CCR4 monoclonal antibody mogamulizumab (KW-0761) in patients
with previously treated peripheral T-cell lymphoma(PTCL)
Novel Drug Combination in T-cell Lymphoma (ND15)
ND15_1
Ai, W
ND15_2
Coiffier, B
ND15_3
Porcu, P
ND15_4
Shustov, A
Development of a drug discovery platform using clinically relevant patient-derived xenograft models
for primary cutaneous and nodal T cell lymphomas
Final analysis of the Ro-CHOP phase Ib/II study: Romidepsin in association with CHOP in uNTREATED
patients with peripheral T-cell lymphoma (PTCL)
Activity of duvelisib, a phosphoinositide-3-Kinase-delta,gamma inhibitor, in patients with
relapsed/refractory T-cell lymphoma
Brentuximab vedotin in combination with CHP in patients with newly diagnosed CD30-positive
peripheral T-cell lymphomas: 2-year follow-up
Oral presentations are bolded
Page 1 of 2
POSTER LISTING
Poster
number
First author’s
last name
CT15_1
CT15_2
CT15_3
CarballoZarate, A
Gibson, J
Hossain, C
CT15_4
Jennings, T
CT15_5
CT15_6
CT15_7
Kamiyama, Y
Kirsch, I
Maerki, J
CT15_8
Perini, G
CT15_9
Safyan, R
Title
Clinical Topics (CT15)
Morphological and immunophenotypic analysis of centrofacial lymphomas from Mexico, with
emphasis on the expression of CD30 and Epstein Barr virus
Outcomes with visceral disease and large cell transformation in mycosis fungoides
Folliculotropism and syringotropism in mycosis fungoides
Rare presentation of aggressive CD4/CD8 double negative immunophenotype in mycosis fungoides
cutaenous T-cell lymphoma
Clinicopathologic features of primary cutaneous anaplastic large cell lymphoma (C-ALCL) with
extracutaneous progression: Long-term follow-up results
High throughput TCR sequencing provides added value in the diagnosis of cutaneous T-cell lymphoma
Unusual presentation of hepatosplenic gamma-delta T-cell lymphoma
CT15_13 Virmani, P
CD8+ peripheral T-cell lymphoma, NOS, with EBV+ Reed-Sternberg-like cells: A case report
Incidence of CNS disease in peripheral T-cell lymphomas: Retrospective analysis from a single north
American institution
Fulminant hemophagocytic lymphohistiocytosis in a patient with EBV-associated extranodal natural
killer/T-cell lymphoma: Case report
A Cutaneous Lymphoma International Consortium (CLIC) Study of prognostic parameters in advanced
stages of mycosis fungoides and sézary syndrome, a step towards establishing a CL prognostic index
Advanced stage mycosis fungoides and Sézary syndrome: how to predict survival and the response to
treatment?
Long-term follow-up of small/medium-sized CD4+ T cell lymphoma and CD8+ lymphoid proliferation of
acral sites: A single center experience
CT15_14 Wang, C
Clinical features of folliculotrophic mycosis fungoides
CT15_10 Safyan, R
CT15_11 Scarisbrick, J
CT15_12 Talpur, R
Improving treatment strategies in PTCL and CTCL (TS15)
TS15_1
Diaz, L
TS15_2
Dong, M
TS15_3
Duvic, M
TS15_4
TS15_5
Duvic, M
Jaramillo, F
TS15_6
Kitahara, H
TS15_7
Kuss, B
TS15_8
Maruyama, D
TS15_9
Pro, B
TS15_10
Shustov, A
TS15_11
Shustov, A
T cell lymphoma refractory with good response to pralatrexate
Gemcitabine-based combination regimens were highly effective and safe in patients with extranodal
natural killer/T-cell lymphoma, nasal type
Responses to romidepsin in patients with cutaneous T-cell lymphoma (CTCL) and prior systemic
chemotherapy: Subanalysis from the pivotal phase 2 study
Phase II trial of brentuximab vedotin (SGN-35) for CD30+ cutaneous T-cell lymphomas and
lymphoproliferative disorders
EPOCH and CHOP in T cell lymphoma. Do we need something else?
A retrospective analysis of 88 patients with peripheral T-cell lymphoma (PTCL) who underwent
CHOP/CHOP-like chemotherapy
Widespread scarring cutaneous ALCL demonstrating dramatic brentuximab-vedotin response at
diagnosis and again at relapse
Early oral care potentially ameliorates mucositis by pralatrexate: Preliminary results in the Japanese
Phase I/II study for relapsed/refractory PTCL
Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic Tcell lymphoma (AITL)
Baseline characteristics, initial treatment and outcomes of patients with CD30+ peripheral T-cell
lymphoma (PTCL): Report from the COMPLETE registry
Phase 3 study of investigational aurora A kinase inhibitor alisertib (MLN8237) vs investigator’s choice
in relapsed/refractory PTCL: Trial in progress
Oral presentations are bolded
Page 2 of 2